miR-1228-5p在原发性肝细胞癌组织和血清中的表达及意义
|
摘要
目的:探讨mi R-1228-5p在原发性肝细胞癌组织和血清中的表达及意义。方法:采用mi RNA快速提取试剂盒分别抽取患者和健康体检者血清中的总mi RNA及患者肝癌组织和癌旁正常肝组织中的总mi RNA,采用实时荧光定量PCR检测总mi RNA中mi R-1228-5p的相对表达量;分析mi R-1228-5p的相对表达量与患者年龄、性别、家族史、肿瘤最大径和临床分期的相关性;此外,用ROC曲线下面积分析mi R-1228-5p在原发性肝细胞癌和健康人群中的诊断价值。结果:原发性肝细胞癌患者血清中mi R-1228-5P的表达量明显高于健康体检者(P<0.05),并且mi R-1228-5P在原发性肝细胞癌组织中的表达量明显高于其癌旁正常肝组织(P<0.05);mi R-1228-5p表达水平与患者的年龄、性别及家族史无关(P>0.05),而与患者的肿瘤最大径和临床分期有关(P<0.05);mi R-1228-5p鉴别原发性肝细胞癌与健康人群中的敏感度和特异度分别为71%和93%。结论:mi R-1228-5p在肝癌患者中的表达水平高于健康人群,且其在肝癌组织中的表达水平高于癌旁正常肝组织。mi R-1228-5p的表达水平与患者的肿瘤最大径和临床分期相关。此外,mi R-1228-5p具有诊断原发性肝细胞癌的潜在价值。
Objective: To investigate the expression and significance of mi R-1228-5 p in the serum of primary liver cancer tissues and patients. Methods: Total mi RNAs in the serum of patients and healthy subjects, total mi RNAs in liver cancer tissues and healthy liver tissues of patients were extracted using mi RNA rapid extraction kit. Real-time quantitative PCR was used to detect the relative mi R-1228-5 p in total mi RNAs. The amount of expression; and the correlation between the relative expression of mi R-1228-5 p and the patient's age, gender, family history, tumor maximum diameter and clinical stage; in addition, the area under the ROC curve was analyzed for mi R-1228-5 p in primary Diagnostic value in liver cancer and healthy people. Results: The expression of serum in patients with primary liver cancer was significantly higher than that in healthy subjects(P<0.05), and the expression of mi R-1228-5 P in the median value of hepatocarcinoma in patients with primary liver cancer was significantly higher than that in normal liver. Organization(P<0.05). The expression level of mi R-1228-5 p was not correlated with the age, gender and family history of the patients(P>0.05), but correlated with the tumor diameter and clinical stage of the patients(P<0.05). In addition, the sensitivity and specificity of mi R-1228-5 p in primary liver cancer and healthy people were 71% and 93%, respectively. Conclusion: The expression level of mi R-1228-5 p in liver cancer patients is higher than that in healthy people, and its expression level in liver cancer tissues is higher than that in normal liver tissues. The expression level of mi R-1228-5 p is related to the tumor's maximum diameter and clinical stage. In addition, mi R-1228-5 p has the potential to diagnose primary liver cancer.
Objective: To investigate the expression and significance of mi R-1228-5 p in the serum of primary liver cancer tissues and patients. Methods: Total mi RNAs in the serum of patients and healthy subjects, total mi RNAs in liver cancer tissues and healthy liver tissues of patients were extracted using mi RNA rapid extraction kit. Real-time quantitative PCR was used to detect the relative mi R-1228-5 p in total mi RNAs. The amount of expression; and the correlation between the relative expression of mi R-1228-5 p and the patient's age, gender, family history, tumor maximum diameter and clinical stage; in addition, the area under the ROC curve was analyzed for mi R-1228-5 p in primary Diagnostic value in liver cancer and healthy people. Results: The expression of serum in patients with primary liver cancer was significantly higher than that in healthy subjects(P<0.05), and the expression of mi R-1228-5 P in the median value of hepatocarcinoma in patients with primary liver cancer was significantly higher than that in normal liver. Organization(P<0.05). The expression level of mi R-1228-5 p was not correlated with the age, gender and family history of the patients(P>0.05), but correlated with the tumor diameter and clinical stage of the patients(P<0.05). In addition, the sensitivity and specificity of mi R-1228-5 p in primary liver cancer and healthy people were 71% and 93%, respectively. Conclusion: The expression level of mi R-1228-5 p in liver cancer patients is higher than that in healthy people, and its expression level in liver cancer tissues is higher than that in normal liver tissues. The expression level of mi R-1228-5 p is related to the tumor's maximum diameter and clinical stage. In addition, mi R-1228-5 p has the potential to diagnose primary liver cancer.
引文
[1]隋晶,刘清华.原发性肝癌的药物治疗进展[J].滨州医学院学报,2018,41(1):56-58.
[2]崔婷婷,杨勇.晚期原发性肝癌药物治疗研究进展[J].药学研究,2018,37(2):108-111.
[3]周婷婷,董会娟,李罗红,等.肝动脉栓塞化疗在中晚期原发性肝细胞癌患者中的疗效观察及术后并发症影响因素研究[J].四川医学,2017,38(8):958-960.
[4]韩丽,刘玉,楚惠媛,等.微小RNA在肝癌的早期诊断、预后监测及治疗中的研究进展[J].临床检验杂志,2015,33(6):457-459.
[5]孙小锦,马琳艳,张梦晓,等.氯喹通过miR-26b调控Mcl-1诱导人肝癌HepG2细胞凋亡[J].南方医科大学学报,2018,38(4):409-413.
[6]温萍,陈盛铎.肝癌组织miR-196b表达变化及其与患者临床病理参数和预后的关系[J].山东医药,2018,58(12):75-77.
[7]王丽萍,孙士萍,华正祥.miR-19a在肝癌组织中高表达对肝癌Hep G2细胞上皮-间质样转化的影响[J].河北医药,2018,40(10):1450-1454.
[8]赵延兵,张玮,赵巧云,等.miR-181-5p通过下调AKT3抑制肝癌细胞侵袭和转移[J].河南科技大学学报(医学版),2018,36(1):15-18.
[9] Tan Y, Ge G, Pan T, et al. A serum microRNA panel as potentialbiomarkers for hepatocellular carcinoma related with hepatitis Bvirus[J]. PloS One, 2014, 9(9):e107986.
[10]周祉妤,聂宏光.miRNA对肺部疾病的研究进展[J].生理科学进展,2018,49(1):57-60.
[11]徐晓彦,吴银洁,尹玲,等.肿瘤组织中微小RNA-335的表达与预后的关系[J].国际肿瘤学杂志,2018,45(4):226-228.
[12] Ding C, He J, Zhao J, et al.β-catenin regulates IRF3-mediatedinnate immune signalling in colorectal cancer[J]. Cell Prolif, 2018,51(5):e12464.
[13]王礼平,卢晓明,阳东荣,等.Ad-pre-microRNA-494抑制Survivin对膀胱癌UM-UC-3细胞的凋亡诱导作用[J].现代泌尿生殖肿瘤杂志,2018,10(1):43-47.
[14]赵兰,何林秀,江龙洋,等.基于生物信息学的胃腺癌组织中miRNA差异表达分析及其临床意义[J].山东医药,2018,58(2):21-24.
[15]彭健,张耀婷,陈杰,等.转铁蛋白的结构功能和潜在临床应用价值[J].中国现代医学杂志,2017,27(26):56-60.
[16]尹智勇,杨俊元,祁宏.Bcl-2蛋白质家族调控细胞凋亡机制的研究进展[J].信阳师范学院学报(自然科学版),2017,30(2):340-344.
[17]范晓红,张喜梅,马玲,等.Mir-204靶向调控Bcl-2影响卵巢癌细胞增殖和凋亡的相关机制研究[J].中国妇产科临床杂志,2018,19(1):48-50.
[18] Wu J, Zhang XJ, Shi KQ, et al. Hepatitis B surface antigen inhibitsMICA and MICB expression via induction of cellular miRNAs inhepatocellular carcinoma cells[J]. Carcinogenesis, 2014, 35(1):155-163.
[19] Ding C, He J, Liao W, et al. Original Article Regulation of WNT/β-catenin signaling by carbamoyl-phosphate synthetase 2, aspar-tate transcarbamylase, and dihydroorotase(CAD)in colorectal can-cer cell[J]. Int J Clin Exp Med, 2017, 10(12):16243-16253.
[20]陈凯,杨洪吉,邓小凡,等.肝癌根治性切除术后早期复发危险因素分析及预测模型构建[J].中华肿瘤防治杂志,2018,25(5):344-348.
[21] Xu J, Li J, Zheng TH, et al. MicroRNAs in the occurrence and de-velopment of primary hepatocellular carcinoma[J]. Adv Clin ExpMed, 2016, 25(5):971-975.
[22] Xu X, Feng G, Wang J, et al. MiR-122-5p inhibits cell migrationand invasion in gastric cancer by down-regulating DUSP4[J]. Can-cer Biol Ther, 2018, 19(5):427-435.
[23]于泳,李霄,周亮,等.MicroRNA-34a、Notch1在肝细胞肝癌组织中的表达及临床意义[J].世界华人消化杂志,2014,22(14):1943-1952.
[24]周泉宇,吴红樱,雷泽华,等.PIVKA-Ⅱ与AFP检测对原发性肝癌的诊断价值[J].海南医学,2018,29(7):960-963.
[2]崔婷婷,杨勇.晚期原发性肝癌药物治疗研究进展[J].药学研究,2018,37(2):108-111.
[3]周婷婷,董会娟,李罗红,等.肝动脉栓塞化疗在中晚期原发性肝细胞癌患者中的疗效观察及术后并发症影响因素研究[J].四川医学,2017,38(8):958-960.
[4]韩丽,刘玉,楚惠媛,等.微小RNA在肝癌的早期诊断、预后监测及治疗中的研究进展[J].临床检验杂志,2015,33(6):457-459.
[5]孙小锦,马琳艳,张梦晓,等.氯喹通过miR-26b调控Mcl-1诱导人肝癌HepG2细胞凋亡[J].南方医科大学学报,2018,38(4):409-413.
[6]温萍,陈盛铎.肝癌组织miR-196b表达变化及其与患者临床病理参数和预后的关系[J].山东医药,2018,58(12):75-77.
[7]王丽萍,孙士萍,华正祥.miR-19a在肝癌组织中高表达对肝癌Hep G2细胞上皮-间质样转化的影响[J].河北医药,2018,40(10):1450-1454.
[8]赵延兵,张玮,赵巧云,等.miR-181-5p通过下调AKT3抑制肝癌细胞侵袭和转移[J].河南科技大学学报(医学版),2018,36(1):15-18.
[9] Tan Y, Ge G, Pan T, et al. A serum microRNA panel as potentialbiomarkers for hepatocellular carcinoma related with hepatitis Bvirus[J]. PloS One, 2014, 9(9):e107986.
[10]周祉妤,聂宏光.miRNA对肺部疾病的研究进展[J].生理科学进展,2018,49(1):57-60.
[11]徐晓彦,吴银洁,尹玲,等.肿瘤组织中微小RNA-335的表达与预后的关系[J].国际肿瘤学杂志,2018,45(4):226-228.
[12] Ding C, He J, Zhao J, et al.β-catenin regulates IRF3-mediatedinnate immune signalling in colorectal cancer[J]. Cell Prolif, 2018,51(5):e12464.
[13]王礼平,卢晓明,阳东荣,等.Ad-pre-microRNA-494抑制Survivin对膀胱癌UM-UC-3细胞的凋亡诱导作用[J].现代泌尿生殖肿瘤杂志,2018,10(1):43-47.
[14]赵兰,何林秀,江龙洋,等.基于生物信息学的胃腺癌组织中miRNA差异表达分析及其临床意义[J].山东医药,2018,58(2):21-24.
[15]彭健,张耀婷,陈杰,等.转铁蛋白的结构功能和潜在临床应用价值[J].中国现代医学杂志,2017,27(26):56-60.
[16]尹智勇,杨俊元,祁宏.Bcl-2蛋白质家族调控细胞凋亡机制的研究进展[J].信阳师范学院学报(自然科学版),2017,30(2):340-344.
[17]范晓红,张喜梅,马玲,等.Mir-204靶向调控Bcl-2影响卵巢癌细胞增殖和凋亡的相关机制研究[J].中国妇产科临床杂志,2018,19(1):48-50.
[18] Wu J, Zhang XJ, Shi KQ, et al. Hepatitis B surface antigen inhibitsMICA and MICB expression via induction of cellular miRNAs inhepatocellular carcinoma cells[J]. Carcinogenesis, 2014, 35(1):155-163.
[19] Ding C, He J, Liao W, et al. Original Article Regulation of WNT/β-catenin signaling by carbamoyl-phosphate synthetase 2, aspar-tate transcarbamylase, and dihydroorotase(CAD)in colorectal can-cer cell[J]. Int J Clin Exp Med, 2017, 10(12):16243-16253.
[20]陈凯,杨洪吉,邓小凡,等.肝癌根治性切除术后早期复发危险因素分析及预测模型构建[J].中华肿瘤防治杂志,2018,25(5):344-348.
[21] Xu J, Li J, Zheng TH, et al. MicroRNAs in the occurrence and de-velopment of primary hepatocellular carcinoma[J]. Adv Clin ExpMed, 2016, 25(5):971-975.
[22] Xu X, Feng G, Wang J, et al. MiR-122-5p inhibits cell migrationand invasion in gastric cancer by down-regulating DUSP4[J]. Can-cer Biol Ther, 2018, 19(5):427-435.
[23]于泳,李霄,周亮,等.MicroRNA-34a、Notch1在肝细胞肝癌组织中的表达及临床意义[J].世界华人消化杂志,2014,22(14):1943-1952.
[24]周泉宇,吴红樱,雷泽华,等.PIVKA-Ⅱ与AFP检测对原发性肝癌的诊断价值[J].海南医学,2018,29(7):960-963.